Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn(BC Cancer Agency), Neil Chua(University of Alberta), Jiřı́ Mayer(Masaryk University), Gregg Dueck(BC Cancer Agency), Marek Trněný(Charles University), Kamal Bouabdallah(Hôpital Cardiologique du Haut-Lévêque), Nathan Fowler(University of Houston), Vincent Delwail(Inserm), Oliver W. Press(Fred Hutch Cancer Center), Gilles Salles(Université Claude Bernard Lyon 1), John G. Gribben(Queen Mary University of London), Anne Lennard(Newcastle University), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Natalie Dimier(Roche (United Kingdom)), Elisabeth Wassner-Fritsch(Roche (Switzerland)), Günter Fingerle‐Rowson(Roche (Switzerland)), Bruce D. Cheson(Georgetown University)
Cited by 342
Abstract
Related Papers
No related papers found
Powered by citation graph analysis